CALL - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 01:53:33 2024-06-14 pm EDT | ||
| 22.41 EUR | +1.45% |
|
| Current month | +9.85% | ||
| 1 month | +12.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 22.41 | +1.45% |
| 24-06-13 | 22.09 | -0.14% |
| 24-06-12 | 22.12 | +0.05% |
| 24-06-11 | 22.11 | -0.99% |
| 24-06-10 | 22.33 | +0.27% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:53 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VF2NSR |
| ISIN | DE000VF2NSR2 |
| Date issued | 2019-02-01 |
| Strike | 161.9 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.41 € |
|---|---|
| Lowest since issue | 0.06 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
